What's new

EMEA-003438-PIP02-23

EMEA-003438-PIP02-23

Mar 18, 2025 0

EMEA-003438-PIP02-23

Seizing opportunities in a changing medicines landscape...

Mar 18, 2025 0

Seizing opportunities in a changing medicines landscape: The European medicines ...

EMEA-003426-PIP01-23

EMEA-003426-PIP01-23

Mar 18, 2025 0

EMEA-003426-PIP01-23

EMEA-003300-PIP01-22

EMEA-003300-PIP01-22

Mar 18, 2025 0

EMEA-003300-PIP01-22

EMA traineeship programme informative session, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 April 2025, 10:00 (CEST) to 14 April 2025, 11:00 (CEST)

EMA traineeship programme informative session, Online, ...

Mar 18, 2025 0

EMA traineeship programme informative session, Online, European Medicines Agency...

Veterinary medicines European public assessment report (EPAR): Cimalgex, cimicoxib, Status: Authorised

Veterinary medicines European public assessment report ...

Mar 17, 2025 0

Veterinary medicines European public assessment report (EPAR): Cimalgex, cimicox...

Veterinary medicines European public assessment report (EPAR): Cytopoint, lokivetmab, Status: Authorised

Veterinary medicines European public assessment report ...

Mar 17, 2025 0

Veterinary medicines European public assessment report (EPAR): Cytopoint, lokive...

Veterinary medicines European public assessment report (EPAR): Leucofeligen FeLV/RCP, feline calicivirosis, feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live), feline leukaemia vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report ...

Mar 17, 2025 0

Veterinary medicines European public assessment report (EPAR): Leucofeligen FeLV...

Human medicines European public assessment report (EPAR): Steglatro, ertugliflozin, Date of authorisation: 21/03/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Steglatro, ertuglifloz...

Human medicines European public assessment report (EPAR): Skilarence, dimethyl fumarate, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Skilarence, dimethyl f...

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, ...

European Organisation for Research and Treatment of Cancer (EORTC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 9 April 2025

European Organisation for Research and Treatment of Can...

Mar 17, 2025 0

European Organisation for Research and Treatment of Cancer (EORTC) bilateral mee...

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, ...

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation: 13/07/2011, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Da...

EMEA-003389-PIP01-23

EMEA-003389-PIP01-23

Mar 17, 2025 0

EMEA-003389-PIP01-23

Methylphenidate product-specific bioequivelance guidance

Methylphenidate product-specific bioequivelance guidance

Mar 17, 2025 0

Methylphenidate product-specific bioequivelance guidance

2024-2026 Work Plan of the Good Clinical Practice Inspe...

Mar 17, 2025 0

2024-2026 Work Plan of the Good Clinical Practice Inspectors Working Group (GCP ...

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Da...

EMEA-002951-PIP02-21

EMEA-002951-PIP02-21

Mar 17, 2025 0

EMEA-002951-PIP02-21

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 17, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, d...

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 17, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (...

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 64, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 17, 2025 0

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Dat...

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0030/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 17, 2025 0

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacopl...

EMEA-002582-PIP03-23

EMEA-002582-PIP03-23

Mar 17, 2025 0

EMEA-002582-PIP03-23

22
23
24
25
26

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.